Skip to content
media1

Zprávy skupiny

  • Aspen concludes two significant agreements with Sandoz for China and Europe
    on 04.12.2023

    Durban, South Africa – JSE-listed Aspen Pharmacare Holdings Limited, a global multinational specialty pharmaceutical company, has announced that Aspen Global Incorporated (“AGI”), its wholly owned subsidiary incorporated in Mauritius, has concluded two interdependent agreements with Sandoz AG (“Sandoz”) concerning the acquisition of Sandoz’s Chinese business and the disposal to Sandoz of four anaesthetic products in… Continue reading Aspen concludes two significant agreements with Sandoz for China and Europe The post Aspen concludes two significant agreements with Sandoz for China and Europe appeared first on Aspen Pharmacare.

  • Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility
    on 19.09.2023

    Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility Durban, South Africa – Aspen is pleased to announce further details on one of the contract manufacturing agreements mentioned in its recent announcement of financial results for the year ended 30 June 2023… Continue reading Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility The post Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility appeared first on Aspen Pharmacare.

  • Aspen revenue exceeds R40 billion with accelerated medium-term growth anticipated
    on 30.08.2023

    Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported a strong performance for the year ended 30 June 2023. SALIENT HIGHLIGHTS Revenue grew by 5% (-3% in constant exchange rate (“CER”)) to R40 709 million (FY2022: R38 606) Normalised EBITDA rose by 1% (-6% in CER) to R11… Continue reading Aspen revenue exceeds R40 billion with accelerated medium-term growth anticipated The post Aspen revenue exceeds R40 billion with accelerated medium-term growth anticipated appeared first on Aspen Pharmacare.

  • Aspen and Lilly enter into agreement in South Africa and the rest of Sub-Saharan Africa
    on 30.08.2023

    Subject to approval from relevant Competition Authorities, Lilly will enter a strategic agreement with Aspen to continue serving patients and bring innovative therapies to South Africa and the rest of Sub-Saharan Africa. Johannesburg – In an effort to improve the reach and expand the access of its innovative portfolio of medicines to the patients who… Continue reading Aspen and Lilly enter into agreement in South Africa and the rest of Sub-Saharan Africa The post Aspen and Lilly enter into agreement in South Africa and the rest of Sub-Saharan Africa appeared first on Aspen Pharmacare.

  • Aspen hosts Mandela Day for 13th consecutive year, having reached 865 000 beneficiaries
    on 18.07.2023

    Durban – JSE Limited listed Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded pharmaceutical company, is participating in Mandela Day for the 13th consecutive year with more than 60 activities in 23 countries.   Stephen Saad, Aspen Group Chief Executive said, “Now, more than ever, communities globally are in desperate need of various… Continue reading Aspen hosts Mandela Day for 13th consecutive year, having reached 865 000 beneficiaries The post Aspen hosts Mandela Day for 13th consecutive year, having reached 865 000 beneficiaries appeared first on Aspen Pharmacare.

Scroll To Top